ExecuPharm main competitors are Gilead Sciences, Corcept Therapeutics, and Merck.

Competitor Summary. See how ExecuPharm compares to its main competitors:

  • Merck has the most employees (74,000).
  • Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
  • The oldest company is Merck, founded in 1891.
Work At ExecuPharm?
E
Share Your Experience

ExecuPharm vs competitors

Company
ascdesc
Founding Date
ascdesc
Zippia Score
ascdesc
Headquarters
ascdesc
# of Locations
ascdesc
Revenue
ascdesc
Employees
ascdesc
1995
4.7
King of Prussia, PA1$76.0M750
1891
4.6
Kenilworth, NJ31$59.3B74,000
1998
4.6
Menlo Park, CA1$401.9M238
1995
4.7
Boston, MA4$70.0M44
1987
4.5
Foster City, CA9$27.3B11,800
1976
4.5
Yardley, PA1$410.0M3,000
1967
4.4
Secaucus, NJ14$9.9B47,000
1944
3.3
Fair Lawn, NJ1$380,00050
2002
4.2
Johnson City, TN2$36.3M278
1989
4.5
Philadelphia, PA9$54.0M1,001

Rate how well ExecuPharm differentiates itself from its competitors.

Zippia waving zebra

ExecuPharm salaries vs Competitors

Among ExecuPharm competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare ExecuPharm Salaries VS Competitors

Company
ascdesc
Average Salary
ascdesc
Hourly Salary
ascdesc
Salary Score
ascdesc
E
ExecuPharm
$93,794$45.09-
M
Merck
$90,328$43.43-
C
Corcept Therapeutics
$99,172$47.68-
I
Intarcia Therapeutics
$76,606$36.83-
G
Gilead Sciences
$99,828$47.99-
M
Medimedia
$52,963$25.46-

Compare ExecuPharm Job Title Salaries VS Competitors

Company
ascdesc
Highest Salary
ascdesc
Hourly Salary
ascdesc
E
ExecuPharm
$38,470$18.50
G
Gilead Sciences
$56,803$27.31
M
Merck
$56,772$27.29
I
Intarcia Therapeutics
$49,824$23.95
L
LabConnect
$46,678$22.44
M
Medimedia
$43,667$20.99
C
Corcept Therapeutics
$43,188$20.76
T
TKL Research
$42,648$20.50
P
Premier Research
$42,553$20.46
Q
Quest Diagnostics
$39,912$19.19
E

Do you work at ExecuPharm?

Does ExecuPharm effectively differentiate itself from competitors?

ExecuPharm Jobs

ExecuPharm demographics vs competitors

Compare Gender At ExecuPharm Vs Competitors

Job TitleascdescMaleascFemaleascdesc
TKL Research30%70%
Quest Diagnostics33%67%
Merck54%46%
Gilead Sciences56%44%
Intarcia Therapeutics68%32%
ExecuPharm--
Male
Female
100%
75%
50%
25%
0%

ExecuPharm: NaN%

ExecuPharm: NaN%

Intarcia Therapeutics: 68%

Intarcia Therapeutics: 32%

Gilead Sciences: 56%

Gilead Sciences: 44%

Merck: 54%

Merck: 46%

Quest Diagnostics: 33%

Quest Diagnostics: 67%

TKL Research: 30%

TKL Research: 70%

0%
25%
50%
75%
100%

Compare Race At ExecuPharm Vs Competitors

Company
ascdesc
White
ascdesc
Hispanic or Latino
ascdesc
Black or African American
ascdesc
Asian
ascdesc
Unknown
ascdesc
Diversity Score
ascdesc
44%20%8%23%6%
9.8
56%16%10%14%4%
9.8
58%17%11%9%4%
9.9
52%21%11%14%3%
8.4
35%17%9%35%4%
9.2
70%11%12%5%2%
6.8

ExecuPharm And Similar Companies CEOs

CEOBio
J
Joseph K. Belanoff M.d
Corcept Therapeutics

Joseph Belanoff is a Chief Executive Officer at CORCEPT THERAPEUTICS INC and is based in United States.

D
Daniel O’Day
Gilead Sciences

R
Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

S
Stephen H. Rusckowski
Quest Diagnostics

Steve Rusckowski is Chairman, President and Chief Executive Officer of Quest Diagnostics. Since joining Quest Diagnostics as President and Chief Executive Officer in May 2012, Mr. Rusckowski has focused on transforming the company, based on its compelling vision of “Empowering better health with diagnostic insights.” Under his leadership, the company has refocused on its core diagnostic information services business, sold non-core assets, delivered disciplined deployment, including share repurchases and acquisitions, and simplified its organizational structure to better serve customers by removing complexity, speeding decision making and empowering employees. He was elected Chairman of the Board in December 2016. Prior to joining Quest Diagnostics, Mr. Rusckowski was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group he was leading at Hewlett-Packard/Agilent Technologies. Mr. Rusckowski is a member of the Board of Directors of Project Hope, a global health education and humanitarian assistance organization. He is also a member of the Board of Directors of the American Clinical Laboratory Association, and served as its Chairman from 2014 to 2017. Mr. Rusckowski earned a Master of Science degree in Management from the Massachusetts Institute of Technology’s Sloan School of Management and a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute.

P
Paul Gaffney
Medimedia

Excited to join the team at Kohl's to drive innovation and change across all aspects of the business.Previously CTO of DICK's Sporting Goods and head of software engineering and applications at The Home Depot. Brought modern practices to software used by hundreds of thousands of associates and millions of customers in stores, online, merchandising, and supply chain. Led customer-centered design solutions that made it easy to work and created a great place to be an engineer.Experienced as CEO of a major regional consumer services organization, CIO of a Fortune 200 company, head of a multi-billion-dollar global retail supply chain, head of technology strategy for one of the most admired financial services firms in the world, and creator of one of the most substantial global e-commerce businesses.* President & CEO of AAA of Northern California, Nevada, and Utah. Over $2.5B in gross sales, and over 2,000 employees in over 100 locations. Turned around financial performance.* Chief Operating Officer, Desktone, Inc. (acquired by VMWare): vision behind VDI product, built product development, software engineering and QA, operations, support, and the CTO function from scratch.* Executive Vice President, head of Supply Chain, Staples: transformed a multi-billion-dollar supply chain into a lean, synchronized operation yielding materially better sales and margin and substantial improvements in working capital. Also EVP & CIO at Staples - led the golbal information systems team to deliver technology innovation and high service levels at industry-leading low costs.* CEO of Website Pros (now web.com): launched the company, raised over $60MM in venture capital, and established long-term strategy that led to an IPO in 2006.* EVP at Office Depot: built one of the world’s largest e-commerce businesses from scratch.* SVP of Technology at Schwab, launched new active trader platform significantly accelerating revenue and profit growth.

L
Ludo Reynders
Premier Research

J
Jon C. Anderson
TKL Research

John Anderson is a President and Chief Executive Officer at TKL RESEARCH INC and is based in Monrovia, California.

Kurt Graves is the Chairman, President and Chief Executive Officer of Intarcia. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Prior to his tenure at Vertex, he spent nearly 10 years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Mr. Graves also previously held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals, where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves earned his B.S. in biology from Hillsdale College and has attended executive leadership programs at Harvard University, the University of Pennsylvania Wharton School of Management and University of Michigan.

D
Dawn Sherman
LabConnect

ExecuPharm Competitors FAQs

Search for jobs

Loading...